

**Grants Awarded through Expression of Interest Process
1 January 2019 to 30 September 2019**

ANTIVIRAL STRATEGIES	
Dr. Cody Allison	Investigating combination clinical-stage SMAC mimetics and Tenofovir alafenamide therapy as an HTLV-1c cure strategy in a humanised mouse model of infection.
A/Prof. Michael Beard	Liver organoid culture as a platform for novel HBV antiviral testing
Prof. Mike Jennings	Repurposing approved medications as oral delivery host targeting inhibitors of HIV transmission
Dr. Clovis Palmer	Immunometabolic impact of Sirolimus therapy on HIV reservoir and immune functions in virologically suppressed-ART-treated HIV+ persons
Prof. Gilda Tachedjian	A novel gel for targeting vaginal inflammation to prevent HIV transmission
DIAGNOSTICS/PROGNOSTICS	
Prof. Bruce Brew	Development of assays in the assessment of central nervous system HIV reservoirs and neuroinflammation in HIV cure interventions.
Dr. Lloyd Einsiedel	HTLV-1c infection and atherosclerosis in Indigenous Australians
Dr. Raffi Gugasyan	Developing a preliminary validation of a prognostic screening test for chronically infected HCV patients
Dr. Jessica Howell	Clinical validation of a point of care ALT test with HBeAg for treatment of chronic HBV infection.
Dr. Jonathan "Jack" Richards	Development of a point-of-care molecular assay for hepatitis C
VACCINE TARGETS	
Dr. Rob Center	De-immunizing the HCV E2 glycoprotein non-neutralizing face
A/Prof. Fasseli Coulibaly	Env-Gag MicroCubes as a vaccine targeting broadly neutralising and mucosal responses
Prof. Hans Netter	Biochemically modified bio-nanoparticles (BNPs) as therapeutic vaccine platforms against hepatitis B
Dr. Pantelis (Andy) Poubourios	A HIV-1 recombinant glycoprotein vaccine that elicits broadly neutralizing antibodies: optimization of the vaccination protocol
IMMUNOTHERAPY	
Prof. Tony Cunningham	Development of gene therapy vectors to reverse interferon inhibition by HIV in myeloid target cells
Dr. Gregor Ebert	Elimination of chronic HBV infection using a monovalent Smac mimetic
Dr. Behnaz Heydarchi	Humanisation of broadly neutralising bovine monoclonal antibodies for HIV cure and prevention
Dr. Julie Nigro	Targetting HBV with engineered T cells
Dr. Thomas Rasmussen	Effect of Immune Checkpoint Inhibitors on HIV Persistence: An observational study among HIV patients with cancer